PUMA BIOTECHNOLOGY, INC.

PBYI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001401667

Price chart

Open-market purchases and sales by PBYI insiders, newest first.

Insider trades
Filed (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
Sep 16, 20269:13 PM ETSep 14, 2026WILSON TROY EDWARDDirectorSSaleCommon Stock−5K$9.10−$45.5K54.75K−8.4%SEC10b5-1
Sep 16, 20269:06 PM ETSep 14, 2026Cesano AlessandraDirectorSSaleCommon Stock−62.15K$9.123−$566.99K56.7K−52.3%SEC10b5-1
Jul 8, 20268:21 PM ETJul 6, 2026AUERBACH ALAN HPresident and CEOSSaleCommon Stock−44.06K$8.263−$364.05K7.26M−0.6%SEC10b5-1
Jul 8, 20268:19 PM ETJul 6, 2026HUNT DOUGLAS MSee RemarksSSaleCommon Stock−8.46K$8.263−$69.9K196.84K−4.1%SEC10b5-1
Jul 8, 20268:18 PM ETJul 6, 2026NOUGUES MAXIMO FChief Financial OfficerSSaleCommon Stock−9.39K$8.263−$77.56K230.64K−3.9%SEC10b5-1

The largest institutional positions in PBYI at the end of Q2 2026.

Institutions holding PBYI in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
ACORN CAPITAL ADVISORS, LLC4,131,299$33.5M9.14%00.0%Unchanged
BlackRock, Inc.3,804,736$30.86M0.00%+205,784+5.7%Added
AMERICAN CENTURY COMPANIES INC2,319,996$18.82M0.01%+403,650+21.1%Added
ACADIAN ASSET MANAGEMENT LLC2,053,523$16.65M0.02%+11,764+0.6%Added
RENAISSANCE TECHNOLOGIES LLC1,836,213$14.89M0.02%−106,200−5.5%Reduced